Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
APLT

APLT - Applied Therapeutics Inc Stock Price, Fair Value and News

5.05USD-0.21 (-3.99%)Market Closed

Market Summary

APLT
USD5.05-0.21
Market Closed
-3.99%

APLT Alerts

  • 2 major insider sales recently.

APLT Stock Price

View Fullscreen

APLT RSI Chart

APLT Valuation

Market Cap

601.0M

Price/Earnings (Trailing)

-3.11

Price/Sales (Trailing)

60.15

Price/Free Cashflow

-8.96

APLT Price/Sales (Trailing)

APLT Profitability

Return on Equity

-287.64%

Return on Assets

-127.99%

Free Cashflow Yield

-11.16%

APLT Fundamentals

APLT Revenue

Revenue (TTM)

10.0M

APLT Earnings

Earnings (TTM)

-193.6M

Earnings Growth (Yr)

-728.04%

Earnings Growth (Qtr)

-122.77%

Breaking Down APLT Revenue

Last 7 days

16.9%

Last 30 days

13.4%

Last 90 days

-12.6%

Trailing 12 Months

267.8%

How does APLT drawdown profile look like?

APLT Financial Health

Current Ratio

1.8

APLT Investor Care

Shares Dilution (1Y)

97.53%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202300010.0M

Tracking the Latest Insider Buys and Sells of Applied Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 06, 2024
shendelman shoshana
sold
-266,954
4.32
-61,795
president and ceo
Jun 06, 2024
perfetti riccardo
sold
-95,053
4.32
-22,003
chief medical officer
Jun 06, 2024
lerner teena
acquired
-
-
45,000
-
Jun 06, 2024
kanter stacy j.
acquired
-
-
45,000
-
Jun 06, 2024
funtleyder leslie d.
sold
-73,353
4.32
-16,980
chief financial officer
Jun 06, 2024
skyler jay s
acquired
-
-
45,000
-
Jun 06, 2024
marcus joel s
acquired
-
-
45,000
-
Jun 05, 2024
alexandria real estate equities, inc.
sold
-636,000
4.24
-150,000
-
Jun 04, 2024
alexandria real estate equities, inc.
sold
-631,500
4.21
-150,000
-
Apr 12, 2024
hooks corwin dale
acquired
-
-
300,000
chief commercial officer

1–10 of 50

Which funds bought or sold APLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Opaleye Management Inc.
added
62.01
8,376,120
12,036,000
2.62%
May 17, 2024
Artal Group S.A.
new
-
6,864,600
6,864,600
0.17%
May 16, 2024
JANE STREET GROUP, LLC
added
85.44
1,221,480
1,663,360
-%
May 16, 2024
COMERICA BANK
unchanged
-
6,900
13,600
-%
May 16, 2024
Connective Capital Management, LLC
sold off
-100
-265,461
-
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
sold off
-100
-170,850
-
-%
May 15, 2024
Soleus Capital Management, L.P.
added
239
9,097,770
10,641,400
0.79%
May 15, 2024
Frazier Life Sciences Management, L.P.
new
-
13,279,400
13,279,400
0.56%
May 15, 2024
Logos Global Management LP
reduced
-18.67
3,415,000
8,976,000
0.73%
May 15, 2024
Parkman Healthcare Partners LLC
added
81.99
9,198,220
12,612,400
1.55%

1–10 of 41

Are Funds Buying or Selling APLT?

Are funds buying APLT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APLT
No. of Funds

Unveiling Applied Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 08, 2024
janus henderson group plc
6.1%
6,414,642
SC 13G
Mar 05, 2024
shendelman shoshana
8.2%
8,646,891
SC 13D/A
Feb 22, 2024
propel bio management, llc
10.5%
8,071,526
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
9.99%
7,877,817
SC 13G/A
Feb 14, 2024
armistice capital, llc
0%
0
SC 13G/A
Feb 14, 2024
alyeska investment group, l.p.
9.99%
7,715,197
SC 13G/A
Feb 14, 2024
perceptive advisors llc
5.9%
4,580,249
SC 13G/A
Feb 14, 2024
orbimed advisors llc
0.0%
0
SC 13G/A
Feb 14, 2024
alexandria real estate equities, inc.
15.4%
12,859,054
SC 13G/A
Feb 13, 2024
vestal point capital, lp
5.4%
4,155,000
SC 13G

Recent SEC filings of Applied Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
Jun 06, 2024
4
Insider Trading
Jun 05, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Applied Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Applied Therapeutics Inc News

Latest updates
MarketBeat20 hours ago

Applied Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q1
Revenue-----10,660
Operating Expenses4.6%21,28320,34015,49517,17621,518
  S&GA Expenses80.0%9,0665,0384,7105,2935,583
  R&D Expenses-20.2%12,21715,30310,78511,88315,935
Net Income-122.8%-83,938-37,679-42,370-29,577-10,137
Net Income Margin-61.6%-19.37*-11.98*---
Free Cashflow-11.2%-18,911-17,005-14,726-16,452-6,990
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets175.8%15155.0045.0044.0030.0038.0057.0078.0065.0090.0011913715610512515116648.0037.0047.0017.00
  Current Assets177.5%15154.0044.0043.0029.0037.0056.0077.0064.0088.0011713515410312314916446.0037.0047.0017.00
    Cash Equivalents193.6%14750.0037.0036.0023.0017.0040.0056.0038.0054.0070.0078.0084.0057.0049.0010193.0019.0013.0041.0015.00
Liabilities16.6%84.0072.0056.0048.0034.0034.0047.0052.0023.0027.0032.0025.0021.0023.0022.0020.0010.0016.007.007.006.00
  Current Liabilities17.9%84.0071.0056.0047.0033.0033.0047.0052.0022.0026.0031.0023.0020.0021.0021.0019.008.0014.007.007.006.00
Shareholder's Equity492.5%67.00-17.15---4.074.0010.0026.0042.0063.0087.0011213582.0010313015633.0031.0040.00-
  Retained Earnings-17.9%-552-468-430-388-359-348-334-315-289-266-239-210-184-160-137-107-79.14-66.77-49.14-38.42-29.99
  Additional Paid-In Capital37.3%62045142038435535334434133132932632332024324023723599.0080.0078.002.00
Shares Outstanding34.6%11485.0077.0062.0056.0048.0048.0027.0026.0026.0025.0026.00---------
Float----64.00---28.00---393---659---68.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-11.2%-18,911-17,005-14,726-16,452-6,990-15,893-19,390-18,400-24,410-26,942-15,665-25,908-22,213-22,750-20,693-15,911-18,855-12,407-7,839-9,059-7,002
  Share Based Compensation46.3%2,3791,6261,8361,8432,0551,9983,2972,2312,0772,8492,6452,7022,9812,5552,4031,7371,3311,3481,2193,279325
Cashflow From Investing-----13,872-6,9055,0215,5299,52511,8078,51816,780-24,67228,444-30,24624,044-41,711----
Cashflow From Financing292.2%115,49729,44616,56729,151-622-933-97130,385-789-1,184-1,0803,49573,4863,093-1,236218134,21918,320-29435,4492,940
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

APLT Income Statement

2024-03-31
Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
REVENUE:  
Total revenue$ 190$ 10,660
COSTS AND EXPENSES:  
Research and development12,21715,935
General and administrative9,0665,583
Total costs and expenses21,28321,518
LOSS FROM OPERATIONS(21,093)(10,858)
OTHER (EXPENSE) INCOME, NET:  
Interest income586221
Change in fair value of warrant liabilities(63,405)469
Other expense(26)31
Total other (expense) income, net(62,845)721
Net loss$ (83,938)$ (10,137)
Net loss per share attributable to common stockholders-basic (in dollars per share)$ (0.67)$ (0.18)
Net loss per share attributable to common stockholders-diluted (in dollars per share)$ (0.67)$ (0.18)
Weighted-average common stock outstanding-basic (in shares)125,318,99356,357,983
Weighted-average common stock outstanding-diluted (in shares)125,318,99356,357,983
License  
REVENUE:  
Total revenue $ 10,660
Research and development services  
REVENUE:  
Total revenue$ 190 

APLT Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 146,484$ 49,898
Security deposits and leasehold improvements253254
Prepaid expenses and other current assets4,1694,234
Total current assets150,90654,386
Operating lease right-of-use asset328447
TOTAL ASSETS151,23454,833
CURRENT LIABILITIES:  
Current portion of operating lease liabilities308429
Accounts payable4,0191,742
Accrued expenses and other current liabilities14,64115,286
Warrant liabilities64,93753,725
Total current liabilities83,90571,182
NONCURRENT LIABILITIES:  
Noncurrent portion of operating lease liabilities3538
Clinical holdback - long-term portion 759
Total noncurrent liabilities35797
Total liabilities83,94071,979
STOCKHOLDERS' EQUITY/(DEFICIT):  
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 114,241,803 shares issued and outstanding as of March 31, 2024 and 84,869,832 shares issued and outstanding as of December 31, 2023118
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Additional paid-in capital619,807451,432
Accumulated deficit(552,524)(468,586)
Total stockholders' (deficit)/equity67,294(17,146)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)$ 151,234$ 54,833
APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
 CEO
 WEBSITEappliedtherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES22

Applied Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Applied Therapeutics Inc? What does APLT stand for in stocks?

APLT is the stock ticker symbol of Applied Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied Therapeutics Inc (APLT)?

As of Thu Jun 13 2024, market cap of Applied Therapeutics Inc is 601.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers. The fair value of Applied Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APLT is over valued or under valued. Whether Applied Therapeutics Inc is cheap or expensive depends on the assumptions which impact Applied Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLT.

What is Applied Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, APLT's PE ratio (Price to Earnings) is -3.11 and Price to Sales (PS) ratio is 60.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLT PE ratio will change depending on the future growth rate expectations of investors.